Outcomes and CAR T-cell persistence in NHL and CLL patients stratified according to pre-CART1 lymphodepletion and CART2 dose relative to CART1. (A) Response rates, (B) PFS, and (C) CAR T-cell persistence by qPCR in NHL and CLL patients according to pre-CART1 lymphodepletion and CART2 dose relative to CART1. Solid lines, Kaplan-Meier estimates; dashed lines; 95% CIs. P values per the log-rank test. Two patients in the pre-CART1 Cy-Flu CART2 > CART1 dose received a CART1 dose of 2 × 10⁵/kg and a CART2 dose of 2 × 10⁶/kg. (C) Bold lines, polynomial regression lines using the LOESS method, shaded areas, 95% CI of the LOESS estimates.